Biosimilars in Pediatric IBD: Updated Considerations for Disease Management

Biologic drugs have significantly modified the pharmacological management of several chronic conditions, including inflammatory bowel diseases (IBD). By contrast, in the last two decades, biologics have been associated with increased direct medical costs. As patents for the reference drugs have expi...

Descripción completa

Detalles Bibliográficos
Autores principales: Dipasquale, Valeria, Cucinotta, Ugo, Romano, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205321/
https://www.ncbi.nlm.nih.gov/pubmed/35721798
http://dx.doi.org/10.2147/BTT.S367032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205321/
https://www.ncbi.nlm.nih.gov/pubmed/35721798
http://dx.doi.org/10.2147/BTT.S367032

Ejemplares similares